By Anthony O. Goriainoff
Novacyt S.A. said Tuesday that it will launch two PathFlow Covid-19 antigen lateral flow tests as it seeks to strengthen its Covid-19 portfolio and pursue new market opportunities, especially in point-of-care settings.
The clinical-diagnostics group, which is listed in London and Paris, said it will initially target private market opportunities through its existing distribution network.
The company said the market is evolving toward private testing and that these tests can be a useful entry point to its current range of PCR Covid-19 tests.
“With the potential for a flu season starting in the northern hemisphere in a few months it will be important to know whether a person has flu or SARS-CoV-2 and having access to quick results are critical to patient treatment and containing the spread of the Covid-19 virus,” Chief Executive Graham Mullis said.
Write to Anthony O. Goriainoff at [email protected]